Dual or Single Antiplatelet Therapy After Transcatheter Aortic Valve Implantation? A Systematic Review and Meta-Analysis.
Transcatheter aortic valve implantation (TAVI) has undeniably earned a prestigious post in the quiver of interventional cardiologists against symptomatic severe aortic stenosis. Cerebrovascular events are listed within the most frequent complications.



We performed a systematic search of EMBASE, MEDLINE, and the Cochrane library from inception to March 2016 for the following search terms (transcatheter AND antiplatelet) OR (transcatheter AND antithrombotic) to retrieve studies of dual antiplatelet treatment (DAPT) and single antiplatelet treatment (SAPT) in patients after TAVI to study thrombotic, hemorrhagic and cardiovascular events at 30 days post procedure. From a total of 208 records 4 studies met inclusion criteria.



In the included studies, 286 patients were enrolled in the DAPT group and 354 patients in the SAPT group. There was no difference in all-cause mortality, cardiovascular mortality, stroke, and myocardial infraction 30 days post TAVI between DAPT and SAPT. However, patients in the DAPT group had a significantly increased incidence of lethal and major bleeding at 30 days of follow-up and the incidence of the combined end-point of stroke, spontaneous MI, all-cause mortality and major bleeding was significantly higher in the DAPT group in comparison to the SAPT group.



DAPT compared to SAPT in patients after TAVI increases incidence of hemorrhagic events with no benefits in terms of thrombotic events and cardiovascular mortality. However, these data must be interpreted cautiously and the choice of DAPT over SAPT must be based on an individual patient characteristic according to medical practice criteria.
VasilissisSofias 114, TK 115 28, Hippokration Hospital, Athens, Greece.
Manolis
M
Vavuranakis
Gerasimos
G
Siasos
Theodoros
T
Zografos
Evangelos
E
Oikonomou
Dimitris
D
Vrachatis
Konstantinos
K
Kalogeras
Theodoros
T
Papaioannou
Michail-Aggelos
MA
Kolokathis
Carmen
C
Moldovan
Dimitrios
D
Tousoulis
D001024:Aortic Valve Stenosis / Q000188:drug therapy* / Q000601:surgery*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D065467:Transcatheter Aortic Valve Replacement
D010975:Platelet Aggregation Inhibitors